Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for EDIT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -119.86M
March 31, 2026 -140.50M
December 31, 2025 -165.24M
September 30, 2025 -179.62M
June 30, 2025 -201.36M
March 31, 2025 -208.21M
December 31, 2024 -210.28M
September 30, 2024 -181.76M
June 30, 2024 -164.63M
March 31, 2024 -146.28M
December 31, 2023 -132.18M
September 30, 2023 -152.21M
June 30, 2023 -164.76M
March 31, 2023 -163.89M
December 31, 2022 -177.35M
September 30, 2022 -169.66M
June 30, 2022 -162.44M
March 31, 2022 -163.55M
December 31, 2021 -163.80M
September 30, 2021 -169.32M
June 30, 2021 -183.34M
March 31, 2021 -175.24M
Date Value
December 31, 2020 -179.84M
September 30, 2020 -98.72M
June 30, 2020 -70.80M
March 31, 2020 -65.75M
December 31, 2019 -40.67M
September 30, 2019 -80.37M
June 30, 2019 -61.32M
March 31, 2019 -52.25M
December 31, 2018 -45.71M
September 30, 2018 -72.10M
June 30, 2018 -92.24M
March 31, 2018 -101.67M
December 31, 2017 -9.417M
September 30, 2017 2.295M
June 30, 2017 13.23M
March 31, 2017 29.49M
December 31, 2016 -49.93M
September 30, 2016 -44.54M
June 30, 2016 -39.44M
March 31, 2016 -9.089M
December 31, 2015 -5.403M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Recursion Pharmaceuticals, Inc. -350.48M
Geron Corp. -114.38M
Halozyme Therapeutics, Inc. 818.60M
Novavax, Inc. -36.90M
AVITA Medical, Inc. -24.71M